Overview
Carcinofibroma of the corpus uteri is an extremely rare type of cancer that develops in the body (corpus) of the uterus, which is the main part of the womb. This tumor is classified as a mixed tumor because it contains two distinct types of abnormal tissue: a carcinoma component (cancer arising from the lining or glandular cells of the uterus) and a fibrous or fibrosarcoma component (cancer arising from the connective tissue). Because it has features of both epithelial and mesenchymal cancers, it falls under the broader category of mixed Müllerian tumors or carcinosarcomas of the uterus, though it is considered a distinct and very rare variant. Symptoms are similar to other uterine cancers and most commonly include abnormal vaginal bleeding, especially bleeding after menopause, pelvic pain, and sometimes a noticeable mass or feeling of fullness in the pelvis. Some patients may experience unexplained weight loss, fatigue, or changes in urinary or bowel habits if the tumor grows large enough to press on nearby organs. Treatment typically involves surgery to remove the uterus (hysterectomy), often along with removal of the ovaries, fallopian tubes, and nearby lymph nodes. Depending on the stage and how far the cancer has spread, additional treatments such as chemotherapy and radiation therapy may be recommended. Because this tumor is so rare, treatment decisions are often guided by experience with more common uterine carcinosarcomas. Early detection and treatment offer the best chance for a favorable outcome, but the mixed nature of this tumor can make it more aggressive than some other uterine cancers.
Key symptoms:
Abnormal vaginal bleeding, especially after menopausePelvic pain or pressureFeeling of fullness or a mass in the lower abdomenUnexplained weight lossFatigue or tirednessWatery or blood-tinged vaginal dischargePain during intercourseChanges in urinary habits such as frequent urinationDifficulty with bowel movementsBloating or swelling in the abdomen
Sporadic
Usually appears on its own, not inherited from a parent
Late onset
Begins later in life, typically after age 50
Treatments
No FDA-approved treatments are currently listed for Carcinofibroma of the corpus uteri.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Carcinofibroma of the corpus uteri at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Carcinofibroma of the corpus uteri.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesHydroxyprogesterone Caproate
Covis
Endometrial Cancer
Travel Grants
No travel grants are currently matched to Carcinofibroma of the corpus uteri.
Community
No community posts yet. Be the first to share your experience with Carcinofibroma of the corpus uteri.
Start the conversation →Latest news about Carcinofibroma of the corpus uteri
No recent news articles for Carcinofibroma of the corpus uteri.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What stage is my cancer, and has it spread beyond the uterus?,What treatment plan do you recommend, and what are the goals of each treatment?,What are the expected side effects of surgery, chemotherapy, and radiation?,Are there any clinical trials that might be appropriate for my type of tumor?,What is my expected prognosis based on the stage and type of my tumor?,How often will I need follow-up visits and scans after treatment?,Should I consider genetic counseling or testing for hereditary cancer syndromes?
Common questions about Carcinofibroma of the corpus uteri
What is Carcinofibroma of the corpus uteri?
Carcinofibroma of the corpus uteri is an extremely rare type of cancer that develops in the body (corpus) of the uterus, which is the main part of the womb. This tumor is classified as a mixed tumor because it contains two distinct types of abnormal tissue: a carcinoma component (cancer arising from the lining or glandular cells of the uterus) and a fibrous or fibrosarcoma component (cancer arising from the connective tissue). Because it has features of both epithelial and mesenchymal cancers, it falls under the broader category of mixed Müllerian tumors or carcinosarcomas of the uterus, thoug
How is Carcinofibroma of the corpus uteri inherited?
Carcinofibroma of the corpus uteri follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Carcinofibroma of the corpus uteri typically begin?
Typical onset of Carcinofibroma of the corpus uteri is late onset. Age of onset can vary across affected individuals.
What treatment and support options exist for Carcinofibroma of the corpus uteri?
1 patient support program are currently tracked on UniteRare for Carcinofibroma of the corpus uteri. See the treatments and support programs sections for copay assistance, eligibility, and contact details.